Mild antithrombin deficiency and risk of recurrent venous thromboembolism: results from the MEGA follow-up study

Journal of Thrombosis and Haemostasis

Volumn 16, Issue 4, 2018, Pages 680-688

  Sokol, J ^a   Timp, J F ^b   le Cessie, S ^b   van Hylckama Vlieg, A ^b   Rosendaal, F R ^b   Kubisz, P ^a   Cannegieter, S C ^b   Lijfering, W M ^b  

^a University Hospital in Martin   (Slovakia)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

antithrombin; deficiency; level; recurrent venous thromboembolism; risk factor

Indexed keywords

ANTITHROMBIN; ANTITHROMBIN III; BIOLOGICAL MARKER;

ADULT; AGED; ANTITHROMBIN DEFICIENCY; ARTICLE; BLEEDING; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HAZARD RATIO; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; RECURRENCE RISK; RISK ASSESSMENT; SURVIVAL; VALIDATION STUDY; VENOUS THROMBOEMBOLISM; ADOLESCENT; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; LUNG EMBOLISM; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; NETHERLANDS; PROGNOSIS; RECURRENT DISEASE; RISK FACTOR; TIME FACTOR; VEIN THROMBOSIS; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTITHROMBIN III; ANTITHROMBIN III DEFICIENCY; BIOMARKERS; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NETHERLANDS; PROGNOSIS; PULMONARY EMBOLISM; RECURRENCE; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; VENOUS THROMBOEMBOLISM; VENOUS THROMBOSIS; YOUNG ADULT;

EID: 85042553162     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.13960     Document Type: Article

References (25)

1. Abildgaard U. Binding of thrombin to antithrombin III. Scand J Clin Lab Invest 1969; 24: 23–7.
2. Damus PS, Hicks M, Rosenberg RD. Anticoagulant action of heparin. Nature 1973; 246: 355–7.
3. Rosenberg RD, Damus PS. The purification and mechanism of action of human antithrombin-heparin cofactor. J Biol Chem 1973; 248: 6490–505.
4. Kurachi K, Fujikawa K, Schmer G, Davie EW. Inhibition of bovine factor IXa and factor Xabeta by antithrombin III. Biochemistry 1976; 15: 373–7.
5. Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet 1999; 353: 1167–73.
6. Lijfering WM, Brouwer JL, Veeger NJ, Bank I, Coppens M, Middeldorp S, Hamulyák K, Prins MH, Büller HR, van der Meer J. Selective testing for thrombophilia in patients with first venous thrombosis: results from a retrospective family cohort study on absolute thrombotic risk for currently known thrombophilic defects in 2479 relatives. Blood 2009; 113: 5314–22.
7. Heijboer H, Brandjes DP, Büller HR, Sturk A, ten Cate JW. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. N Engl J Med 1990; 323: 1512–6.
8. Tait RC, Walker ID, Islam SI, McCall F, Conkie JA, Mitchell R, Davidson JF. Influence of demographic factors on antithrombin III activity in a healthy population. Br J Haematol 1993; 84: 476–80.
9. Di Minno MND, Dentali F, Lupoli R, Ageno W. Mild antithrombin deficiency and risk of recurrent venous thromboembolism. Circulation 2014; 129: 497–503.
10. Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005; 293: 715–22.
11. Flinterman LE, van Hylckama Vlieg A, Cannegieter SC, Rosendaal FR. Long-term survival in a large cohort of patients with venous thrombosis: incidence and predictors. PLoS Med 2012; 9: e1001155.
12. Flinterman LE, van Hylckama Vlieg A, Rosendaal FR, Cannegieter SC. Body height, mobility, and risk of first and recurrent venous thrombosis. J Thromb Haemost 2015; 13: 548–54.
13. Stricker BH, Herings RM. [Plea for the retention of the Dutch National Medical Registration (LMR) to provide reliable information regarding public health and healthcare]. Ned Tijdschr Geneeskd 2006; 150: 1916–7.
14. Schalekamp T, Klungel OH, Souverein PC, de Boer A. Effect of oral antiplatelet agents on major bleeding in users of coumarins. Thromb Haemost 2008; 100: 1076–83.
15. de la Morena-Barrio ME, Martínez-Martínez I, de Cos C, Wypasek E, Roldán V, Undas A, van Scherpenzeel M, Lefeber DJ, Toderici M, Sevivas T, España F, Jaeken J, Corral J, Vicente V. Hypoglycosylation is a common finding in antithrombin deficiency in the absence of a SERPINC1 gene defect. J Thromb Haemost 2016; 14: 1549–60.
16. Meltzer ME, Lisman T, Doggen CJ, de Groot PG, Rosendaal FR. Synergistic effects of hypofibrinolysis and genetic and acquired risk factors on the risk of a first venous thrombosis. PLoS Med 2008; 5: e97.
17. Christiansen SC, Cannegieter SC, Koster T, Vandenbroucke JP, Rosendaal FR. Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA 2005; 293: 2352–61.
18. Bezemer ID, van der Meer FJ, Eikenboom JC, Rosendaal FR, Doggen C. The value of family history as a risk indicator for venous thrombosis. Arch Intern Med 2009; 169: 610–5.
19. Verduijn M, Grootendorst DC, Dekker FW, Jager KJ, le Cessie S. The analysis of competing events like cause-specific mortality–beware of the Kaplan-Meier method. Nephrol Dial Transplant 2011; 26: 56–61.
20. Baglin T, Luddington R, Brown K, Baglin C. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet 2003; 362: 523–6.
21. Roach RE, Venemans A, Cannegieter SC, Lijfering WM. Differential risks in men and women for first and recurrent venous thrombosis: the role of genes and environment: reply. J Thromb Haemost 2015; 13: 886–7.
22. Di Minno MN, Ambrosino P, Ageno W, Rosendaal F, Di Minno G, Dentali F. Natural anticoagulants deficiency and the risk of venous thromboembolism: a meta-analysis of observational studies. Thromb Res 2015; 135: 923–32.
23. Carrier M, Le Gal G, Wells PS, Rodger MA. Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism. Ann Intern Med 2010; 152: 578–89.
24. Meijer K, Schulman S. The absence of ‘minor’ risk factors for recurrent venous thromboembolism: a systematic review of negative predictive values and negative likelihood ratios. J Thromb Haemost 2009; 7: 1619–28.
25. Lijfering WM, Rosendaal FR, Cannegieter SC. Risk factors for venous thrombosis - current understanding from an epidemiological point of view. Br J Haematol 2010; 149: 824–33.